WO2024068744 - ANTIVIRALS AGAINST HUMAN PARAINFLUENZA VIRUS
National phase entry:
Publication Number
WO/2024/068744
Publication Date
04.04.2024
International Application No.
PCT/EP2023/076723
International Filing Date
27.09.2023
Title **
[English]
ANTIVIRALS AGAINST HUMAN PARAINFLUENZA VIRUS
[French]
ANTIVIRAUX DIRIGÉS CONTRE LE VIRUS PARAINFLUENZA HUMAIN
Applicants **
VIB VZW
UNIVERSITEIT GENT
Inventors
SAELENS, Xavier
ROSSEY, Iebe
SCHEPENS, Bert
NAUWYNCK, Hans
Priority Data
22197948.7
27.09.2022
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2352 | |
| EPO | Filing, Examination, Granting | 9414 | |
| Japan | Filing, Examination, Granting | 2155 | |
| South Korea | Filing, Examination, Granting | 2071 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
20,732
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The invention relates to antigen-binding protein agents specifically binding the hemagglutinin- neuraminidase (HN) protein of human parainfluenza virus 3 (hPIV-3), with cross-reactivity for Sendai Virus (SeV) as well as human parainfluenza virus serotype 1 (hPIV-1) HN, resulting in a cross-neutralizing binding protein to act as a protection agent against parainfluenza infection and/or disease caused by such an infection. More specifically, the invention relates to a family of immunoglobulin single variable domains (ISVDs) capable of broadly blocking HN neuraminidase activity, thereby providing for a novel hPIV-1/-3 cross-neutralizing antiviral protein binding agent. The invention further relates to the use of said antigen-binding proteins in prevention or treatment of acute respiratory tract infections, croup, pneumonia, and exacerbations of chronic obstructive pulmonary disease.[French]
L'invention concerne des agents protéiques de liaison à l'antigène se liant de manière spécifique à la protéine hémagglutinine-neuraminidase (HN) du virus parainfluenza humain 3 (hPIV-3), avec une réactivité croisée pour le virus Sendai (SeV) ainsi que le sérotype 1 du virus parainfluenza humain (hPIV-1) HN, conduisant à une protéine de liaison à neutralisation croisée pour agir en tant qu'agent de protection contre une infection parainfluenza et/ou une maladie provoquée par une telle infection. Plus particulièrement, l'invention concerne une famille de domaines variables uniques d'immunoglobuline (ISVD) capables de bloquer largement l'activité de la neuraminidase HN, ce qui permet d'obtenir un nouvel agent de liaison à la protéine antivirale de neutralisation croisée hPIV-1/-3. L'invention concerne en outre l'utilisation desdites protéines de liaison à l'antigène dans la prévention ou le traitement d'infections des voies respiratoires aiguës, du croup, de la pneumonie et des exacerbations de la bronchopneumopathie chronique obstructive.